Category: 1003709-39-4

On April 14, 2022, Kuduk, Scott; Pietsch, Eva Christine; Guttke, Christina D.; Bush, Tammy L. published a patent.Related Products of 1003709-39-4 The title of the patent was Preparation of substituted isoquinolinones as dihydroorotate dehydrogenase inhibitors for use in combinations with hypomethylating agents. And the patent contained the following:

Disclosed are methods of treating a subject who has been diagnosed with a disease, syndrome, condition, or disorder affected by DHODH enzymic activity comprising administering: a therapeutically effective amount of a DHODH inhibitor I [X = CH or N; Y = CH or N; R1 = (un)substituted alkyl, haloalkyl, cycloalkyl, etc.; R2 = II (wherein Ra = alkyl, haloalkyl, cycloalkyl; Rb = (un)substituted alkyl); R3 = H, halo, Me and OMe; R4 = (un)substituted alkyl, cycloalkyl, pyridyl, etc.], a therapeutically effective amount of a hypomethylating agent and optionally, a therapeutically effective amount of a BCL-2 inhibitor. E.g., a multi-step synthesis of III, starting from Et 2-(benzyloxy)acetate and hydrazine hydrate, was described. The latter was assessed for its ability to induce cytotoxicity in 30 primary AMF patient samples by Cell TiterGlo assay. Eighteen of the AMF samples were highly sensitive to the compound III resulting in IC50 values between 0.11 and 95.1 nM, one patient sample had an IC50 value of 469.1 nM and the remaining 11 cases demonstrated little sensitivity to III with the highest concentration evaluated (3000 nM) unable to kill more than 50% of the tumor cells. The experimental process involved the reaction of 2-Bromo-4-fluoro-5-methylbenzoic acid(cas: 1003709-39-4).Related Products of 1003709-39-4

The Article related to isoquinolinone preparation dihydroorotate dehydrogenase inhibitor combination chemotherapy hypomethylating agent, dhodh inhibitor combination chemotherapy hypomethylating agent isoquinolinone preparation, combination chemotherapy dhodh bcl2 inhibitor hypomethylating agent isoquinolinone preparation and other aspects.Related Products of 1003709-39-4

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On May 22, 2014, Dominique, Romyr; Lopez-Tapia, Francisco Javier; Mertz, Eric; So, Sung-Sau published a patent.Recommanded Product: 2-Bromo-4-fluoro-5-methylbenzoic acid The title of the patent was Preparation of substituted pyridinones as inhibitors of bruton’s tyrosine kinase. And the patent contained the following:

The title compounds I [A = (un)substituted unsaturated or partially saturated monocyclic or bicyclic heteroaryl or phenyl; R1 = halo, hydroxyalkyl, alkyl; m = 0-2; R2 = Me, pyrazolyl; n = 0-1; X = a bond, CH2, NHC(O)], useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity, were prepared E.g., a multi-step synthesis of II, starting from 6-tert-butyl-8-fluoro-2H-phthalazin-1-one and 1-bromo-4-chloromethylbenzene, was described. Exemplified compounds I were evaluated for their Btk inhibitory activity (data given). The compounds I are useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds I and at least one carrier, diluent or excipient. The experimental process involved the reaction of 2-Bromo-4-fluoro-5-methylbenzoic acid(cas: 1003709-39-4).Recommanded Product: 2-Bromo-4-fluoro-5-methylbenzoic acid

The Article related to pyridinone phthalazinone preparation bruton’s tyrosine kinase btk inhibitor antiinflammatory, phthalazinone oxopyridinylbenzyl preparation auto immune disease aberrant bcell proliferation, rheumatoid arthritis treatment antirheumatic pyridinone phthalazinone preparation btk inhibitor and other aspects.Recommanded Product: 2-Bromo-4-fluoro-5-methylbenzoic acid

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On October 15, 2015, Dominique, Romyr; Lopez-Tapia, Francisco Javier; Mertz, Eric; So, Sung-Sau published a patent.Application In Synthesis of 2-Bromo-4-fluoro-5-methylbenzoic acid The title of the patent was Inhibitors of bruton’s tyrosine kinase. And the patent contained the following:

This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. The experimental process involved the reaction of 2-Bromo-4-fluoro-5-methylbenzoic acid(cas: 1003709-39-4).Application In Synthesis of 2-Bromo-4-fluoro-5-methylbenzoic acid

The Article related to pyridinone phthalazinone preparation brutons tyrosine kinase btk inhibitor antiinflammatory, phthalazinone oxopyridinylbenzyl preparation auto immune disease aberrant bcell proliferation, rheumatoid arthritis treatment antirheumatic pyridinone phthalazinone preparation btk inhibitor and other aspects.Application In Synthesis of 2-Bromo-4-fluoro-5-methylbenzoic acid

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary